dc.creator | Stamati P., Siokas V., Aloizou A.-M., Karampinis E., Arseniou S., Rakitskii V.N., Tsatsakis A., Spandidos D.A., Gozes I., Mitsias P.D., Bogdanos D.P., Hadjigeorgiou G.M., Dardiotis E. | en |
dc.date.accessioned | 2023-01-31T10:01:58Z | |
dc.date.available | 2023-01-31T10:01:58Z | |
dc.date.issued | 2019 | |
dc.identifier | 10.1007/s12031-019-01363-3 | |
dc.identifier.issn | 08958696 | |
dc.identifier.uri | http://hdl.handle.net/11615/79367 | |
dc.description.abstract | Α number of genetic variants have been associated with Alzheimer’s disease (AD) susceptibility. Sec1 family domain-containing protein 1 (SCFD1) gene polymorphism rs10139154 has recently been implicated in the risk of developing amyotrophic lateral sclerosis (ALS). Similarities in the pathogenetic cascade of both diseases have also been described. The present study was designed to evaluate the possible contribution of SCFD1 rs10139154 to AD. A total of 327 patients with AD and an equal number of healthy controls were included in the study and genotyped for rs10139154. With logistic regression analyses, rs10139154 was examined for the association with the risk of developing AD. In the recessive mode, SCFD1 rs10139154 was associated with a decreased risk of developing AD (odds ratio (OR) (95% confidence interval (CI)) = 0.63 (0.40–0.97), p = 0.036). The current study provides preliminary evidence of the involvement of SCFD1 rs10139154 in the risk of developing AD. © 2019, Springer Science+Business Media, LLC, part of Springer Nature. | en |
dc.language.iso | en | en |
dc.source | Journal of Molecular Neuroscience | en |
dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85068779862&doi=10.1007%2fs12031-019-01363-3&partnerID=40&md5=3b41e913e2d3923aa3296b75d08fa3ee | |
dc.subject | membrane protein | en |
dc.subject | Sec1 family domain containing protein 1 | en |
dc.subject | unclassified drug | en |
dc.subject | Sly1 protein, human | en |
dc.subject | vesicular transport adaptor protein | en |
dc.subject | aged | en |
dc.subject | Alzheimer disease | en |
dc.subject | Article | en |
dc.subject | controlled study | en |
dc.subject | female | en |
dc.subject | gene frequency | en |
dc.subject | genetic association | en |
dc.subject | genetic risk | en |
dc.subject | genotype | en |
dc.subject | human | en |
dc.subject | major clinical study | en |
dc.subject | male | en |
dc.subject | single nucleotide polymorphism | en |
dc.subject | Alzheimer disease | en |
dc.subject | genetics | en |
dc.subject | very elderly | en |
dc.subject | Adaptor Proteins, Vesicular Transport | en |
dc.subject | Aged | en |
dc.subject | Aged, 80 and over | en |
dc.subject | Alzheimer Disease | en |
dc.subject | Female | en |
dc.subject | Humans | en |
dc.subject | Male | en |
dc.subject | Polymorphism, Single Nucleotide | en |
dc.subject | Springer New York LLC | en |
dc.title | Does SCFD1 rs10139154 Polymorphism Decrease Alzheimer’s Disease Risk? | en |
dc.type | journalArticle | en |